Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOTIV: Moxifloxacin vs Levofloxacin + Ceftriaxone in Severe CAP
NCT00431678Phase 3Completed
- Sponsor
- Bayer
- Start
- Jan 2004
- Primary completion
- Jul 2005
- Modality
- Orthosteric Ligands
- Countries
- 18
01
Overview
Phase 3, randomised, double-blind trial of moxifloxacin in community acquired pneumonia (CAP) (2 arms), sponsored by Bayer. Primary endpoint: Clinical Response. Started Jan 2004; status: completed.
02
Drugs
moxifloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00431678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00431678.